How do Kisqali and Ibrance compare head-to-head?
Kisqali (ribociclib) and Ibrance (palbociclib) are both CDK4/6 inhibitors used with endocrine therapy for hormone receptor-positive (HR+), HER2-negative advanced breast cancer. No head-to-head trials directly prove one is superior overall. Both extend progression-free survival (PFS) versus endocrine therapy alone, but cross-trial comparisons show Kisqali edging out in some metrics.1
| Trial | Drug | Median PFS (months) | OS Data |
|-------|------|---------------------|---------|
| MONALEESA-2 (Kisqali + letrozole, 1st line) | 25.3 | Interim OS benefit (53.4 vs 51.4 mo)2 |
| PALOMA-2 (Ibrance + letrozole, 1st line) | 24.8 | No OS benefit3 |
| MONALEESA-7 (Kisqali + tamoxifen/AI, pre/peri-menopausal) | 23.8 | OS benefit (58.7 vs 48.0 mo)4 |
| PALOMA-3 (Ibrance + fulvestrant, 2nd line+) | 9.5 | No OS benefit5 |
Kisqali shows OS improvements in MONALEESA trials, unlike Ibrance's PALOMA series. Real-world data from Flatiron Health echoes this, with Kisqali-linked PFS at 20+ months vs Ibrance's 14-17 months in similar groups.6
Does Kisqali improve survival more than Ibrance?
Yes, in indirect comparisons. Network meta-analyses rank Kisqali highest for PFS and OS in first-line settings (HR 0.71-0.75 vs placebo; better than Ibrance's HR 0.80).7 FDA approvals reflect this: Kisqali gained full first-line nod based on OS; Ibrance relies on PFS.
What about side effects—does one have fewer issues?
Both cause neutropenia (Kisqali 74%, Ibrance 80%), fatigue, and nausea. Kisqali has higher QT prolongation risk (worsens heart rhythm; monitor ECG), while Ibrance sees more early discontinuations (13% vs 7% for Kisqali).1 Liver enzyme elevations hit Kisqali harder. Dose reductions are common for both (Kisqali 51-71%, Ibrance 42-66%).
Which is cheaper or easier to get?
Ibrance launched first (2015, Pfizer), so generics loom post-patent expiry (2034, with challenges).9 Kisqali (2017, Novartis) patents run to 2034; no generics yet.10 List prices: ~$14K/month for both, but patient assistance varies. Insurance often covers equally.
Can you switch from Ibrance to Kisqali?
Yes, after progression on Ibrance. Trials like MAINTAIN and PACE support switching CDK4/6 inhibitors, with ~30% PFS benefit.11 Guidelines (NCCN) allow it for HR+/HER2- metastatic cases.
Who makes them and what's the patent outlook?
- Ibrance: Pfizer; key patents expire 2034, but ANDA filings challenge earlier (e.g., 2023 litigation).9
- Kisqali: Novartis; composition patent to 2034, with pediatric extensions possible.10
For patent details, check DrugPatentWatch.com.
Sources